Acute COVID-19 does not affect corneal sensitivity, study finds

Article

Investigators theorize that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

Acute COVID-19 does not affect corneal sensitivity, study finds

Brazilian researchers reported recently that the corneal esthesiometry findings did not differ significantly between patients who had positive and negative polymerase chain reaction (PCR) results for COVID-19, indicating that the acute infection did not impact the ability to obtain reliable test results.1

A team of investigators, led by Dr Lucas Baldissera Tochetto from the Department of Ophthalmology and Visual Science at Federal University of Sao Paulo in Sao Paulo, Brazil, reported their results in the British Journal of Ophthalmology.

A number of ocular manifestations of COVID-19 have previously been reported, and Dr Tochetto pointed out that SARS-CoV-2 RNA was found in the tear film or conjunctival swabs in patients tested using PCR.2 Based on that, the investigators theorized that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

A total of 202 individuals who were suspected of having COVID-19 based on symptomatology participated in this cross-sectional study. All subjects underwent testing for SARS-CoV-2 by nasopharyngeal reverse-transcription qualitative PCR.

All patients also underwent corneal esthesiometry measurements using the Cochet-Bonnet esthesiometer (Luneau Ophthalmologie) during their first visit and the measurements were analyzed based on the findings, presence of anosmia and dysgeusia, and ocular signs and symptoms, Dr Tochetto said.

PCR testing and corneal sensitivity

PCR identified COVID-19 infections in 101 subjects (50%). The mean corneal esthesiometry findings based on the PCR results did not differ significantly when the baseline and first follow-up visit were compared, demonstrating that the virus did not affect the corneal esthesiometry in individuals with acute-phase COVID-19. The mean time from symptom onset to disease diagnosis and corneal esthesiometry was 4.2 days, he noted.

Fifty of the patients who tested positive for COVID-19 also were examined a second time. The mean time between the first to second visits was 32.5 days. The mean respective corneal esthesiometry measurements in the right eye at the 2 evaluations were 5.52 and 5.60 (p=0.616) and for the left eye 5.40 and 5.58 (p=0.173).

The authors concluded that their results indicated that the SARS-CoV-2 infection did not interfere with corneal esthesiometry, at least, in the mild and early stages of this disease.

References
1. Baldissera Tochetto L, de Freitas Santoro D, Hirai F, et al. Impact of COVID-19 on corneal esthesiometry. Br J Ophthalmol 2022; http://dx.doi.org/10.1136/bjophthalmol-2021-320003
2. Sarma P, Kaur H, Kaur H, et al. Ocular manifestations and tear or conjunctival swab PCR positivity for 2019-nCoV in patients with COVID-19: a systematic review and meta-analysis. SSRN Electron J 2020; doi:10.2139/ssrn.3566161
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.